Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07205926 · ClinicalTrials.gov registry record · Phase 1
First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults
A Phase 1 study of Diarrhea and Shigella, sponsored by Inventprise.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07205926 is a Phase 1 study of Diarrhea and Shigella that is actively recruiting participants, run by Inventprise. The registered enrollment target is 60 participants, below the 155-participant average among 24 other Diarrhea trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07205926, a Phase 1 study of Diarrhea and Shigella, is actively recruiting participants, sponsored by Inventprise.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 1 trial to evaluate the Safety and Immunogenicity of Inventprise's (IVT) Shigella-04 in Healthy Young Adults
Interventions
- BIOLOGICAL IVT Shigella-04
- BIOLOGICAL Placebo (0.9% saline)
Study Locations (1)
Ohio
- Medpace Clinical Pharmacology Unit - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-10-09 |
| Est. Completion | 2026-08-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07205926
The ClinicalTrials.gov registry entry for NCT07205926 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 155-participant average among 24 other Diarrhea trials with a reported enrollment target (61% lower). The listed sponsor is Inventprise, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diarrhea appearing as the primary indexed condition, and to 2 interventions - of which IVT Shigella-04 is the first listed.
NCT07205926 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07205926 about?
NCT07205926 is a clinical study titled "First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults". Phase 1 trial to evaluate the Safety and Immunogenicity of Inventprise's (IVT) Shigella-04 in Healthy Young Adults
What is the current status of trial NCT07205926?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-10-09. Estimated completion is 2026-08-21.
What conditions does trial NCT07205926 study?
This clinical trial studies the following conditions: Diarrhea, Shigella.
What interventions are being tested in trial NCT07205926?
The interventions under investigation include: IVT Shigella-04 (BIOLOGICAL), Placebo (0.9% saline) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07205926?
This trial is sponsored by Inventprise, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07205926 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diarrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
RECRUITING · Phase 1
-
A Study of SER-155 to Treat Diarrhea in People on Immunotherapy
RECRUITING · Phase 1
-
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
COMPLETED · Phase 1
-
Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]
COMPLETED · Phase 1
-
Invaplex 50 Vaccine Dose-Ranging
COMPLETED · Phase 1
-
GI Alpha-Gal Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.